| 摘要 |
The pharmaceutical compositions contain moxonidine (4-chloro-6- methoxy-2-methyl-5-(2-imidazolin-2-yl)aminopyrimidine) or its pharmaceutically acceptable salts and hydrochlorothiazide (6-chloro- 3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide) and optionally triamterene (2,4,7-triamino-6-phenylpteridine). |
